NasdaqCM - Nasdaq Real Time Price USD

Aligos Therapeutics, Inc. (ALGS)

Compare

39.84

+1.49

(+3.89%)

At close: December 20 at 4:00:02 PM EST

40.41

+0.57

(+1.43%)

After hours: December 20 at 7:57:22 PM EST

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week

Key Insights Significant control over Aligos Therapeutics by retail investors implies that the general public has more...

Simply Wall St. 15 hours ago

ALGS
+3.89%
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company’s stock (the “Inducement Grant”) to a newly hired empl

GlobeNewswire 8 days ago

ALGS
+3.89%
Aligos Therapeutics to Present at Investor Conferences in December

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two investor conferences being webcast in December: Piper Sandler 36th Annual Healthcare Conference Fireside Chat at 11:00am ET/8:00am PT on December 3, 2024 Evercore ISI 7th Annual HealthCONx C

GlobeNewswire 25 days ago

ALGS
+3.89%
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. Th

GlobeNewswire last month

ALGS
+3.89%
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Aligos Therapeutics ( NASDAQ:ALGS ) Third Quarter 2024 Results Key Financial Results Net loss: US$19.3m (loss widened...

Simply Wall St. last month

ALGS
+3.89%
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -42.79% and 26.90%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ALGS
+3.89%
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024. “This quarter we reached a key milestone when we announced the positive topline HERALD data in MASH subjects,” stated Lawrence Blatt, Ph.D., MBA, Chairm

GlobeNewswire last month

ALGS
+3.89%
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2024 financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage bioph

GlobeNewswire last month

ALGS
+3.89%
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) for a Phase 1 Drug-Drug Inte

GlobeNewswire last month

ALGS
+3.89%
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced four abstracts have been accepted, including one late-breaker oral presentation and three poster presentations, at the American Association for the

GlobeNewswire 2 months ago

ALGS
+3.89%
Aligos Therapeutics Appoints David Perry as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. “We are pleased to welcome David to the Aligos team during this exciting time for the company,” said Lesley Ann Calhoun, Executive Vice Pres

GlobeNewswire 2 months ago

ALGS
+3.89%
Aligos Therapeutics to Present at Investor Conferences in October

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October: H.C. Wainwright 8th Annual MASH Virtual Conference Fireside Chat at 3:00pm ET/12:00pm PT on October 7, 2024 H.C. Wainwright 5th Annual Vi

GlobeNewswire 2 months ago

ALGS
+3.89%
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achnec

GlobeNewswire 2 months ago

HAE

ALGS
+3.89%
NONOF
Aligos reports positive data from Phase IIa MASH treatment trial

In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

Clinical Trials Arena 2 months ago

ALGS
+3.89%
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lip

GlobeNewswire 3 months ago

ALGS
+3.89%
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on

GlobeNewswire 3 months ago

ALGS
+3.89%
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks 3 months ago

ALGS
+3.89%
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

ALGS
+3.89%
Aligos Therapeutics Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company’s common stock is expected begi

GlobeNewswire 4 months ago

ALGS
+3.89%
What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

ALGS
+3.89%

Performance Overview

Return	ALGS	S&P 500
YTD	+140.00%	+24.34%
1-Year	+170.10%	+24.38%
3-Year	-86.74%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics to Present at Investor Conferences in December

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics to Present at Investor Conferences in October

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Aligos reports positive data from Phase IIa MASH treatment trial

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

Aligos Therapeutics Announces Reverse Stock Split

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Performance Overview